UK regulators have granted approval for human trials of an experimental Ebola vaccine, marking the first such candidate to enter clinical testing among four vaccines under development. The vaccine was designed by researchers at the University of Oxford, beginning their work eight weeks after the declaration of a public health emergency on 17 May.
The ongoing outbreak, centered in the Democratic Republic of the Congo, has resulted in 625 deaths and 1,792 laboratory-confirmed cases. The strain responsible is the Bundibugyo species of Ebola, which kills approximately one-third of those infected. The outbreak remains active in a conflict zone with highly mobile populations, creating urgency for vaccine development and distribution.
The trial will enroll 50 healthy adults aged 18-55 in the United Kingdom, with plans to expand testing to Africa through partnerships in Uganda. Participants will be monitored for one year, allowing researchers to assess immune response and identify any unexpected side effects. The Serum Institute of India has manufactured approximately 620,000 doses to clinical standards.
The Oxford team leveraged technology that gained prominence during the Covid-19 pandemic. The vaccine platform uses a genetically modified chimpanzee cold virus as a delivery mechanism for genetic material from the Bundibugyo Ebola species. This approach enables the immune system to recognize and respond to the virus without causing infection. Researchers note that all standard safety and efficacy testing protocols are being followed, though multiple teams work in parallel to accelerate the timeline compared to traditional vaccine development.
Three additional vaccine candidates are in development, including an mRNA-based approach from Moderna and candidates using proven techniques for other Ebola species. Vaccine developers emphasized that expedited timelines do not involve cutting corners on safety protocols, though researchers acknowledged potential rare side effects similar to those observed with the Oxford-AstraZeneca Covid vaccine, which affected up to one in 100,000 recipients.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI